

## SAFETY DATA SHEET

Issuing Date 25-Sep-2007 Revision Date 22-Dec-2014 **Revision Number** 2

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

**GHS** product identifier

**Product Name** ALPHAGAN® P (Brimonidine Tartrate Ophthalmic Solution), 0.10% and 0.15%

Other means of identification

**Synonyms** None

Recommended use of the chemical and restrictions on use

**Recommended Use** alpha-adrenergic receptor

Uses advised against No information available

Supplier's details

**Supplier Address** Allergan, Inc. 2525 Dupont Irvine, CA

TEL: 1-714-246-4500

**Emergency telephone number** 

**Emergency Telephone** 

Number

Chemtrec 1-800-424-9300

## 2. HAZARDS IDENTIFICATION

Classification

Specific Target Organ Toxicity (Repeated Exposure)

Category 2

## GHS Label elements, including precautionary statements

## **Emergency Overview**

Signal Word Warning

May cause damage to the cardiovascular system through prolonged or repeated exposure.



Odor Slight Appearance Clear, Liquid Physical State Liquid.

Page 1/8

#### **Precautionary Statements**

#### Prevention

· Do not breathe dust/fume/gas/mist/vapors/spray.

#### **General Advice**

• Get medical attention/advice if you feel unwell

#### Storage

None

#### Disposal

• Dispose of contents/container to an approved waste disposal plant.

#### **Hazard Not Otherwise Classified (HNOC)**

Not applicable

#### Other information

Repeated ocular use has been shown to produce oral dryness, eye irritation, ocular allergic reactions, headache or fatigue or drowsiness when used as directed. Ocular allergies have also been shown in sensitive individuals (fewer than 10% of all clinical subjects).

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS-No	Weight %	Trade secret
Brimonidine tartrate	70359-46-5	0.1-0.15	*

<sup>\*</sup> Where range is displayed, the exact percentage (concentration) of composition has been withheld as a trade secret.

## 4. FIRST AID MEASURES

## **Description of necessary first-aid measures**

**Eye Contact** Rinse thoroughly with plenty of water, also under the eyelids. Get medical attention if

irritation persists.

Skin Contact Wash skin with soap and water. Get medical attention if symptoms occur.

**Inhalation** IF INHALED: If breathing is difficult, remove to fresh air and keep at rest in a position

comfortable for breathing. Get medical attention.

Ingestion Clean mouth with water and afterwards drink plenty of water. Do NOT induce vomiting. Get

medical attention.

#### Most important symptoms/effects, acute and delayed

Most Important Symptoms/Effects Irregular cardiac activity. Central nervous system depression. Headache. Eye

irritation/reactions.

## Indication of immediate medical attention and special treatment needed, if necessary

Notes to Physician Treat symptomatically.

## 5. FIRE-FIGHTING MEASURES

#### Suitable Extinguishing Media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

\_\_\_\_\_

Unsuitable Extinguishing Media No information available.

#### **Specific Hazards Arising from the Chemical**

No information available.

**Explosion Data** 

Sensitivity to Mechanical Impact None.
Sensitivity to Static Discharge None.

#### **Protective Equipment and Precautions for Firefighters**

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

## 6. ACCIDENTAL RELEASE MEASURES

#### Personal precautions, protective equipment and emergency procedures

Personal Precautions Avoid contact with skin, eyes and clothing. Do not touch damaged containers or spilled

material unless wearing appropriate protective clothing. Refer to Section 8 for personal

protective equipment.

Environmental Precautions

**Environmental Precautions** See Section 12 for additional Ecological Information.

#### Methods and materials for containment and cleaning up

Methods for Containment Small spills: Wipe up with absorbent material (e.g. cloth, fleece). Large spills: Prevent

further leakage or spillage if safe to do so. Contain and collect spillage with

non-combustible absorbent material, (e.g. sand, earth, diatomaceous earth, vermiculite) and place in container for disposal according to local / national regulations (see Section 13).

**Methods for Cleaning Up**Clean contaminated surface thoroughly.

## 7. HANDLING AND STORAGE

#### Precautions for safe handling

Handling Handle in accordance with good industrial hygiene and safety practice. Avoid contact with

skin, eyes and clothing. Wear personal protective equipment. Refer to Section 8.

## Conditions for safe storage, including any incompatibilities

Storage Keep containers tightly closed in a dry, cool and well-ventilated place.

**Incompatible Products** Oxidizing agents.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control parameters

**Exposure Guidelines** Allergan OEL: Brimonidine Tartrate: 12.5 ug/m<sup>3</sup> (8 hr. TWA)

Chemical Name	ACGIH TLV	OSHA PEL	NIOSH IDLH
Boric acid	TWA: 2 mg/m <sup>3</sup> inhalable fraction	-	-
10043-35-3	STEL: 6 mg/m <sup>3</sup> inhalable fraction		
Sodium borate	STEL: 6 mg/m <sup>3</sup> inhalable	(vacated) TWA: 10 mg/m <sup>3</sup>	TWA: 5 mg/m <sup>3</sup>
1303-96-4	fraction	, ,	-
	TWA: 2 mg/m <sup>3</sup> inhalable fraction		

\_\_\_\_\_

#### **Appropriate engineering controls**

Engineering Measures Showers

Eyewash stations Ventilation systems

#### Individual protection measures, such as personal protective equipment

Eye/Face Protection No special protective equipment required. If splashes are likely to occur, wear: Safety

glasses with side-shields.

Skin and Body Protection No protective equipment is needed under normal use conditions. Risk of contact:

Lightweight protective clothing. Protective gloves.

**Respiratory Protection** None required under normal usage.

Handle in accordance with good industrial hygiene and safety practice. Do not eat, drink or

smoke when using this product. Keep away from food, drink and animal feeding stuffs. Provide regular cleaning of equipment, work area and clothing. Remove and wash

None known

contaminated clothing and gloves, including the inside, before re-use. Wash hands before

breaks and immediately after handling the product.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

#### Information on basic physical and chemical properties

Physical State Liquid Appearance Clear Liquid

Odor Slight Odor Threshold No information available

PropertyValuesRemarks/ - MethodpH7.1-7.3None known

pН None known Melting Point/Range None known No data available **Boiling Point/Boiling Range** >100 °C / >212 °F None known >93.33 °C / >200 °F Flash Point None known **Evaporation rate** No data available None known Flammability (solid, gas) No data available None known

Flammability Limits in Air

upper flammability limitNo data availablelower flammability limitNo data availableVapor PressureNo data available

**Vapor Density** No data available None known **Specific Gravity** 1.0 None known **Water Solubility** Soluble in water. None known Solubility in other solvents No data available None known Partition coefficient: n-octanol/waterNo data available None known **Autoignition Temperature** No data available None known **Decomposition Temperature** No data available None known **Viscosity** No data available None known

Flammable Properties Not flammable

Explosive Properties No data available Oxidizing Properties No data available

**Other information** 

VOC Content (%) No data available

#### 10. STABILITY AND REACTIVITY

#### Reactivity

Not reactive under normal conditions.

## **Chemical stability**

Stable under recommended storage conditions.

#### Possibility of hazardous reactions

None under normal processing.

## **Hazardous Polymerization**

Hazardous polymerization does not occur.

#### **Conditions to avoid**

Heat.

#### **Incompatible materials**

Oxidizing agents.

#### **Hazardous decomposition products**

None known.

## 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

**Product Information** 

**Inhalation** Not an expected route of exposure. Inhalation of mist may cause irritation to the respiratory

system.

**Eye Contact** May cause eye irritation with susceptible persons. Repeated ocular use has been shown to

produce oral dryness, eye irritation, ocular allergic reactions, headache or fatigue or drowsiness when used as directed. Ocular allergies have also been shown in sensitive

individuals (fewer than 10% of all clinical subjects).

**Skin Contact** Prolonged skin contact may cause skin irritation.

**Ingestion** May cause irritation to the gastrointestinal tract. Ingestion of large quantities may cause

central nervous system effects.

**Component Information** Brimonidine Tartrate (active ingredient): Oral LD50 = 50 mg/kg (mouse); 100 mg/kg (rat).

Clinical signs included sedation, ataxia, prostration, ptosis, reduced blink reflex,

hypotension, hypothermia, respiratory depression/arrest, and circulatory collapse. At 10 mg/kg, transient decreased motor activity, ataxia and/or prostration were observed in both

species.

Chemical Name	LD50 Oral	LD50 Dermal	LC50 Inhalation
Brimonidine tartrate	100 mg/kg ( Rat )	-	-
	50 mg/kg ( Mouse )		

## Symptoms related to the physical, chemical and toxicological characteristics

**Symptoms** Prolonged or repeated exposure can cause central nervous system effects.

## Delayed and immediate effects and also chronic effects from short and long term exposure

**Sensitization** No information available.

Mutagenic Effects Brimonidine Tartrate was not mutagenic or cytogenic in a series of in vitro and in vivo

studies including the Ames test, host-mediated assay, chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells, cytogenic studies in mice and dominant lethal assay. Did not show carcinogenic effects in animal experiments. Contains no ingredient listed as a

carcinogen.

Reproductive Toxicity

Developmental Toxicity

STOT - single exposure

Animal testing did not show any effects on fertility.

Animal testing did not show any effects on fetal development.

Based on available data, the classification criteria are not met.

STOT - repeated exposure May cause damage to organs through prolonged or repeated exposure. See listed target

organs below.

Chronic Toxicity Oral administration of Brimonidine Tartrate (active ingredient) for one year in rats resulted in

toxicity only at the high dose (1.0 mg/kg/day). All changes were reversible within the 8 week recovery period. In monkeys, administration of Brimonidine Tartrate for one year resulted in sedation, slight hypotension, sinus bradycardia, and occasionally, sinus arrhythmia at a dose of 2.5 mg/kg/day. No observable effects were noted at a dose of 0.1 mg/kg/day.

Brimonidine Tartrate at varying concentrations was administered in repeated doses (one drop into one eye twice per day) to rabbits for six months and monkeys for one year. Rabbits exhibited dose-dependent sedation at the 0.5 % concentration but not at the 0.2%

concentration.

Target Organ EffectsCardiovascular system.Aspiration HazardNo information available.

Numerical measures of toxicity - Product

LD50 Oral >5000 mg/kg; Acute toxicity estimate

#### 12. ECOLOGICAL INFORMATION

#### **Ecotoxicity**

Carcinogenicity

The environmental impact of this product has not been fully investigated.

Taviaituta Alaaa

Chemical Name	Toxicity to Algae	Toxicity to Fish	Toxicity to	Daphnia Magna (Water
			Microorganisms	Flea)
Boric acid		LC50 72 h: = 1020 mg/L		EC50 48 h: 115 - 153 mg/L
10043-35-3		flow-through (Carassius		(Daphnia magna)
		auratus)		
Sodium Chloride		LC50 96 h: 4747-7824		EC50 48 h: 340.7 - 469.2
7647-14-5		mg/L flow-through		mg/L Static (Daphnia
		(Oncorhynchus mykiss)		magna)
		LC50 96 h: 5560-6080		EC50 48 h: = 1000 mg/L
		mg/L flow-through (Lepomis		(Daphnia magna)
		macrochirus)		
		LC50 96 h: 6020-7070		
		mg/L static (Pimephales		
		promelas)		
		LC50 96 h: 6420-6700		
		mg/L static (Pimephales		
		promelas)		
		LC50 96 h: = 12946 mg/L		
		static (Lepomis macrochirus)		
		LC50 96 h: = 7050 mg/L		
		semi-static (Pimephales		
		promelas)		
Sodium borate	EC50 96 h: = 158 mg/L	LC50 96 h: = 340 mg/L		LC50 48 h: 1085 - 1402
1303-96-4	(Desmodesmus subspicatus)	(Limanda limanda)		mg/L (Daphnia magna)
	EC50 96 h: 2.6 - 21.8 mg/L			
	static (Pseudokirchneriella			
	subcapitata)			

# WPS-ALL-007 - ALPHAGAN® P (Brimonidine Tartrate Ophthalmic Solution), 0.10% and 0.15%

Sodium chlorite	LC50 96 h: 100 - 500 mg/L	EC50 48 h: 0.012 - 0.018
7758-19-2	static (Brachydanio rerio)	mg/L Static (Daphnia
	LC50 96 h: > 100 mg/L static	magna)
	(Lepomis macrochirus)	EC50 48 h: 0.25 - 0.33
	LC50 96 h: > 100 mg/L static	mg/L Flow through (Daphnia
	(Oncorhynchus mykiss)	magna)
		EC50 48 h: = 0.026 mg/L
		(Daphnia magna)

Persistence and Degradability No information available.

**Bioaccumulation** No information available.

## **Other Adverse Effects**

No information available.

## 13. DISPOSAL CONSIDERATIONS

Waste Disposal Methods Dispose of in accordance with local regulations.

**Contaminated Packaging** Do not re-use empty containers.

## 14. TRANSPORT INFORMATION

**DOT** Not regulated.

TDG Not regulated.

MEX Not regulated.

IATA Not regulated.

IMDG/IMO Not regulated.

## 15. REGULATORY INFORMATION

**International Inventories** 

TSCA Exempt
DSL Exempt

<u>Legend</u>

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

## U.S. Federal Regulations

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

#### SARA 311/312 Hazard Categories

Acute Health HazardYesChronic Health HazardYesFire HazardNoSudden Release of Pressure HazardNoReactive HazardNo

\_\_\_\_\_\_

## Clean Water Act

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

#### **CERCLA**

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

## U.S. State Regulations

#### California Proposition 65

This product does not contain any Proposition 65 chemicals.

#### U.S. State Right-to-Know Regulations

This product does not contain any substances above threshold limits that are regulated by state right-to-know.

Chemical Name	New Jersey	Massachusetts	Pennsylvania	Illinois	Rhode Island
Boric acid				X	

#### U.S. EPA Label Information

EPA Pesticide Registration Number Not applicable

16. OTHER INFORMATION					
NFPA_	Health Hazard 1	Flammability	0 Instal	oility 0	Physical and Chemical Hazards -
HMIS	Health Hazard 1	* Flammability	0 Physi	cal Hazard 0	Personal Protection X

Prepared By Product Stewardship

23 British American Blvd. Latham, NY 12110

| 1-800-572-6501 |
| Issuing Date | 25-Sep-2007 |
| Revision Date | 22-Dec-2014 |
| Revision Note | Update to Format.

### General Disclaimer

The information provided on this SDS is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guide for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered as a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other material or in any process, unless specified in the text.

**End of Safety Data Sheet**